Looking Into Intra-Cellular Therapies's Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting in a loss of $69.14 million.
Benzinga · 8h ago
Jefferies Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $70
Jefferies analyst Andrew Tsai maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $55 to $70.
Benzinga · 10h ago
BRIEF-Intra-Cellular Therapies Announces Publications Of Beneficial Effects Of Phosphodiesterase Type I Inhibition With Lenrispodun · 11h ago
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (Circulation: Heart Failure; Gilotra, et al, 2021)
GlobeNewswire · 11h ago
Jefferies Adjusts Intra-Cellular Therapies' Price Target to $70 From $55, Keeps Buy Rating
MT Newswires · 12h ago
Intra-Cellular Therapies Says Lenrispodun Study Showed Positive Results in Patients With Heart Failure
MT Newswires · 13h ago
Analysts Differ Most About Potential for Novo's Weight-Loss Drug
GuruFocus News · 09/07 19:38
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 08/16 12:52
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon ...
GlobeNewswire · 08/10 12:00
--RBC Capital Adjusts Intra-Cellular Therapies PT to $45 From $47, Maintains Outperform Rating
MT Newswires · 08/10 08:44
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -7.59% and 8.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/09 13:05
Intra-Cellular Therapies: Q2 Earnings Insights
  Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year to ($0.85), which missed the estimate of ($0.80).
Benzinga · 08/09 11:52
BRIEF-Intra-Cellular Therapies Reports Q2 Results · 08/09 11:39
Intra-Cellular Therapies Q2 EPS $(0.85) Misses $(0.80) Estimate, Sales $20.05M Beat $19.44M Estimate
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.80) by 6.25 percent. This is a 11.46 percent increase over losses of $(0.96) per
Benzinga · 08/09 11:35
Intra-Cellular Therapies Q2 Loss Shrinks as Revenue Surges
MT Newswires · 08/09 08:26
-- Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q2 Revenue $20M
MT Newswires · 08/09 07:45
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Cooper Buys Intra-Cellular Therapies Inc, Broadstone Net Lease Inc, NVIDIA Corp, Sells Mogo ...
GuruFocus News · 08/04 18:38
Will Intra-Cellular Therapies (ITCI) Report Negative Q2 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/02 19:01
Intra-Cellular Therapies Sponsored Study Titled 'Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder' Posted To ClinicalTrials.Gov Site; Study Is Recruiting
Benzinga · 08/02 13:53
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about INTRA CELLULAR through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.